The global ”depression treatment therapy market” size is expected to gain momentum backed by the increasing incidence of suicides and the growing number of psychiatrists that is likely to boost the adoption of advanced depression treatment therapy modules worldwide. This information is published by Fortune Business Insights in its upcoming report, titled, “Depression Treatment Therapy Market Size, Share & Industry Analysis, By Type (Medications, Devices), By Disease Indication (Major Depression, Bipolar Depression, Seasonal Affective Disorder (SAD), Premenstrual Dysphoric Disorder (PMDD), Others), By End User (Hospitals, Specialty Clinics, Others) and Regional Forecast 2020-2027.”
The effect of the global pandemic, COVID-19, has been felt across several economies that are facing unprecedented loss. Owing to the lockdown announced by the government agencies, several industries have been on a standstill with limited operational activities. However, a collective effort from the government as well as the industries is likely to bring the economy back on track and aid in resumption of industrial activities.
There are about 264 million people who suffer from some type of mental illness across the globe, according to the World Health Organization. The depression treatment therapy has witnessed significant changes due to technological advancement and growing awareness amongst the general population.
Request a Sample Copy of the Research Report:
Increasing Incidence of Depression Disorders in North America to Augment Growth
Among all the regions, North America is expected to hold the highest position in the global depression treatment therapy market during the forecast period. This is attributable to the increasing incidence of depression disorders in countries such as the U.S. that is propelling the demand for advanced depression treatment therapy procedures in the region between 2020 and 2027.
The market in Asia-Pacific is expected to experience substantial growth backed by the growing demand for effective drug therapies in the region.
What does the Report Include?
The market report includes qualitative and quantitative analysis of several factors such as the key drivers and restraints that will impact growth. Additionally, the report provides insights into the regional analysis that covers different regions, contributing to the growth of the market. It includes the competitive landscape that involves the leading companies and the adoption of strategies to announce partnerships, introduce new products, and collaborate that will further contribute to the growth of the market between 2020 and 2027. Moreover, the research analyst has adopted several research methodologies such as SWOT and PESTEL analysis to extract information about the current trends and industry developments that will drive the market growth during the forecast period.
Have Any Query? Ask Our Experts:
Major Companies Focus on Investment in R&D Activities to Brighten Their Market Prospects
The global depression treatment therapy market comprises small, medium, and large companies that are striving to maintain a stronghold. The companies are investing in R&D activities to develop effective depression treatment therapy solutions to cater to the growing need amongst patients. Moreover, other key players are adopting organic and inorganic growth strategies that are likely to bode well for the market growth.
- November 2020 – Janssen, a global pharma firm, announced its partnership with Koa Health, a leading digital mental healthcare provider. Together, the companies will work to provide effective digital treatment for patients suffering from depression and further strengthen their positions in the global market for depression treatment therapy.
List of the Companies Operating in the Global Market for Depression Treatment Therapy:
- Pfizer Inc.
- Teva Pharmaceuticals
- Merck & Co. Inc.
- Johnson & Johnson
- Eli Lilly and Company
- Novartis International AG
- Sanofi S.A.
- AstraZeneca PLC
What are the key segments in the market?
Global Depression treatment therapy market Segmentation :
o Selective Serotonin Reuptake Inhibitors
o Atypical Antidepressants
o Tricyclic Antidepressants
o Transcranial Magnetic Device
o Deep Brain Stimulator
o Vagus Nerve Stimulator
By Disease Indication
- Major Depression
- Bipolar Depression
- Seasonal Affective Disorder (SAD)
- Premenstrual Dysphoric Disorder (PMDD)
By End User
- Specialty Clinics
- North America (USA, Canada)
- Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
- Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
- Latin America (Brazil, Mexico, Rest of Latin America)
- Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
With tables and figures helping analyse worldwide Global depression treatment therapy market Forecast provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune – 411045, Maharashtra, India.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Related Reports :